Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Jacinta Abraham"'
Publikováno v:
Medicine. 51:28-31
Autor:
Erika Hitre, Carlo Tondini, Marco Sequi, Flavia Morales-Vásquez, Jacinta Abraham, Servando Cardona-Huerta, Zbigniew Nowecki, Jose Perez-Garcia, Miguel Martin, Sherko Kuemmel, Estefania Monturus, Eleonora Restuccia, Bartosz Itrych, Mark C. Benyunes, Boguslawa Karaszewska, Alejandro Juárez-Ramiro
Publikováno v:
Breast Cancer Research and Treatment
Purpose Intravenous trastuzumab, pertuzumab, and docetaxel are first-line standard of care for patients with HER2-positive metastatic breast cancer (mBC). MetaPHER is the first study assessing the safety and tolerability of subcutaneous trastuzumab p
Autor:
Myria Nikolaou, Timothy J. Perren, Gia Nemsadze, Richard D. Baird, Robert McEwen, Daniel Stetson, Duncan Wheatley, A.M. Brunt, Hayley Cartwright, Max McLaughlin-Callan, Jean-Marc Ferrero, Peter Schmid, Cheryl Lawrence, Jacinta Abraham, Nicholas C. Turner, László Mangel, Melissa Phillips, Matthew Burgess, Peter Hall, John Conibear, Andrew Foxley, Aaron Prendergast, Kelly Mousa, Robert Stein, Yeon Hee Park, Javier Cortes, Stephen Chan, Elza C. de Bruin, Brian Dougherty
Publikováno v:
Cancer Research. 81:PD1-11
Background: In the PAKT study, addition of the oral AKT inhibitor capivasertib to 1st-line paclitaxel therapy for metastatic TNBC resulted in significantly longer progression-free survival (PFS; primary endpoint; Schmid, J Clin Oncol 2020). The strat
Autor:
Matthew C Winter, Daniel Rea, Jacinta Abraham, Olga Oikonomidou, Iain R. Macpherson, David Cameron, Jeremy P Braybrooke, Sarah Kernaghan, Andrew M Wardley, Heidrun Gevensleben, Laura Moretti, Mark Tuthill, Katrina Randle, Peter Stephens, A Ring, Mike Hubank, Judith M Bliss, Rebecca Roylance, Abeer M Shaaban, Hannah Bye, Lucy Kilburn, Sue Martin, B Kingston, Katie Wilkinson, Nicholas C. Turner, Claire Snowdon, Ros Cutts, Richard D. Baird
Publikováno v:
C Turner, N, Kingston, B, S Kilburn, L, Kernaghan, S, M Wardley, A, R Macpherson, I, D Baird, R, Roylance, R, Stephens, P, Oikonomidou, O, P Braybrooke, J, Tuthill, M, Abraham, J, C Winter, M, Bye, H, Hubank, M, Gevensleben, H, Cutts, R, Snowdon, C, Rea, D, Cameron, D A, Shaaban, A, Randle, K, Martin, S, Wilkinson, K, Moretti, L, Bliss, J M & Ring, A 2020, ' Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial ', The Lancet Oncology, vol. 21, no. 10, pp. 1296-1308 . https://doi.org/10.1016/S1470-2045(20)30444-7
BACKGROUND: Circulating tumour DNA (ctDNA) testing might provide a current assessment of the genomic profile of advanced cancer, without the need to repeat tumour biopsy. We aimed to assess the accuracy of ctDNA testing in advanced breast cancer and
Autor:
Matthew C Winter, Daniel Rea, Peter Stephens, Rebecca Roylance, Nicholas C. Turner, Jeremy P Braybrooke, Hannah Bye, Lucy Kilburn, Claire Snowdon, Sarah Kernaghan, Iain R. Macpherson, Judith M Bliss, Richard D. Baird, Mike Hubank, Abeer M Shaaban, Andrew M Wardley, Katie Wilkinson, Alistair Ring, Mark Tuthill, Jacinta Abraham, Katrina Randle, Belinda Kingston, David Cameron, Olga Oikonomidou, Laura Moretti
Publikováno v:
Cancer Research. 80:GS3-06
Background: Circulating tumour DNA (ctDNA) testing may provide a more current assessment of the genetic profile of advanced breast cancer (BC) compared with analysis of the primary tumour, with repeat advanced disease biopsy conducted infrequently in
Autor:
Jose Manuel Perez Garcia, Erika Hitre, Boguslawa Karaszewska, Jacinta Abraham, Eleonora Restuccia, Carlo Tondini, Alejandro Juarez, Mark C. Benyunes, Miguel Martín, Zbigniew Nowecki, Adam Knott, Sherko Kümmel, Bartosz Itrych, Flavia Morales-Vásquez, Servando Cardona-Huerta, Marco Sequi, Estefania Monturus
Publikováno v:
Cancer Research. 80:P1-18
Background Previous trials showed that fixed-dose subcutaneous trastuzumab and hyaluronidase-oysk (Herceptin Hylecta™; H SC) was non-inferior to weight-based intravenous trastuzumab (Herceptin®; H IV) in terms of pathologic complete response and s
Autor:
Peter Stephens, Belinda Kingston, Andrew M Wardley, Nicholas C. Turner, Iain R. Macpherson, Rebecca Roylance, Judith M Bliss, Jeremy P Braybrooke, Richard D. Baird, Sarah Kernaghan, Mark Tuthill, Olga Oikonomidou, Jacinta Abraham, Lucy Kilburn, Katie Wilkinson, Matthew C Winter, Alistair Ring
Publikováno v:
Cancer Research. 80:P1-19
Background: Activation of the AKT pathway can result from diverse rare genetic events, including mutation of AKT1, AKT2/3 E17K, and through inactivating mutation or homozygous deletion of PTEN. AKT1 mutations and genetic loss of PTEN are associated w
Autor:
Iain R. Macpherson, Alistair Ring, Andrew M Wardley, Katie Wilkinson, Lucy Kilburn, Peter Stephens, Rebecca Roylance, Mark Tuthill, Olga Oikonomidou, Matthew C Winter, Nicholas C. Turner, Richard D. Baird, Jacinta Abraham, Belinda Kingston, Jeremy P Braybrooke, Sarah Kernaghan, Judith M Bliss
Publikováno v:
Cancer Research. 80:P1-19
Background: HER2 mutations occur in approximately 3% of HER2 non-amplified cancers and include missense substitutions and indels within the tyrosine kinase domain resulting in oncogenic HER2 activation. Neratinib, an irreversible EGFR, HER2 and ERBB4
Autor:
Iain R. Macpherson, Matthew C Winter, Mark Tuthill, Rebecca Roylance, Alistair Ring, Peter Stephens, Belinda Kingston, Andrew M Wardley, Katie Wilkinson, Olga Oikonomidou, Nicholas C. Turner, Jacinta Abraham, Lucy Kilburn, Jeremy P Braybrooke, Sarah Kernaghan, Judith M Bliss, Richard D. Baird
Publikováno v:
Cancer Research. 80:P1-19
Background: AKT1 mutation occurs in approximately 3% of breast cancer (BC), enriched in advanced BC. The AKT1 E17K mutation results in constitutive activation of AKT1, associated with sensitivity to AKT inhibitor capivasertib in pre-clinical models,
Autor:
Sherko Kümmel, Carlo Alberto Tondini, Jacinta Abraham, Zbigniew Nowecki, Bartosz Itrych, Erika Hitre, Bogusława Karaszewska, Alejandro Juárez-Ramiro, Flavia Morales-Vásquez, Jose Manuel Pérez García, Servando Cardona-Huerta, Estefania Monturus, Marco Sequi, Eleonora Restuccia, Mark Benyunes, Miguel Martín
BACKGROUND Intravenous trastuzumab, pertuzumab, and docetaxel is first-line standard of care for patients with HER2-positive metastatic breast cancer. Subcutaneous trastuzumab plus intravenous pertuzumab and chemotherapy has shown similar safety and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5aeb92fb722a9202804359a5ce85f8fd
https://doi.org/10.21203/rs.3.rs-57692/v1
https://doi.org/10.21203/rs.3.rs-57692/v1